Sarcopenia as a leading component of malignant cachexia syndrome
Abstract
The aim of review. To analyze cumulative data of the global literature on skeletal musculature depletion or sarcopenia, in development of malignant cachexia syndrome, as well as diagnostics and clinical value of this state.
Original points. Cachexia syndrome is one of the most frequent consequences of malignant disease. In the last years it was demonstrated, that sarcopenia plays the leading role in pathogenesis and progression of this state. Various procedures, including anthropometry, bioimpedance analysis, dual photon X-ray absorptiometry can be applied in diagnostics of sarcopenia. However, computer and magnetic-resonance tomography have the highest value for this goal. The article presents in detail data on clinical value of sarcopenia along with academical aspects of body composition analysis by radiological methods. Perspective trends of scientific studies in this area are proposed.
Conclusion. Sarcopenia is the important component of malignant cachexia syndrome. Its investigation is perspective trend in clinical studies in oncology.
About the Authors
V. K. Lyadov
ФГУ «Лечебно-реабилитационный центр Минздравсоцразвития РФ»
Russian Federation
Russian Federation
E. A. Bulanova
ФГУ «Лечебно-реабилитационный центр Минздравсоцразвития РФ»
Russian Federation
Russian Federation
A. P. Seryakov
ФГУ «Лечебно-реабилитационный центр Минздравсоцразвития РФ»
Russian Federation
Russian Federation
References
1. Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010; 21:1594–8.
2. Argilés JM, Anker SD, Evans WJ, et al. Consensus on cachexia definitions. J Am Med Dir Assoc. 2010; 11(4):229–30.
3. Baracos VE. Pitfalls in defining and quantifying cachexia. J Cachexia Sarcopenia Muscle. 2011; 2:71–3.
4. Baracos VE, Reiman T, Mourtzakis M, et al. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. J Clin Nutr. 2010; 91(suppl):1133–7.
5. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New
6. Mexico. Am J Epidemiol. 1998; 147(8): 755–63.
7. Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis and emerging treatment strategies. Annu Rev Med. 2011; 62:1–15.
8. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489–95.
9. Fearon KCH, Baracos VE. Cachexia in pancreatic cancer: new treatment options and measures of success. HPB. 2010; 12:323–4.
10. Heymsfield SB, Wang ZM, Baumgartner RN, Ross R. Human body composition: advances in models and methods. Annu Rev Nutr. 1997; 17:527–58.
11. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons associated with functional impairment and physical disability. J Am Geriatr Soc. 2002; 50(5):889–96.
12. Kim H, Kim CH, Kim DW, et al. External crossvalidation of bioelectrical impedance analysis for the assessment of body composition in Korean adults. Nutr Res Pract. 2011; 5(3):246–52.
13. Kumar NB, Kazi A, Smith T, et al. Cancer cachexia: traditional therapies and novel molecular mechanism based approaches to treatment. Curr Treat Options Oncol. 2010; 11:107–17.
14. Lieffers JR, Mourtzakis M, Hall KD, et al. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr. 2009; 89:1173–9.
15. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998; 85:115–22.
16. Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33(5):997–1006.
17. Palesty JA, Dudrick SJ. What we have learned about cachexia in gastrointestinal cancer. Dig Dis. 2003; 21:198–213.
18. Prado CMM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-Fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007; 13(11):3264–8.
19. Prado CMM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9:629–35.
20. Prado CMM, Lima ISF, Baracos VE, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011; 67:93–101.
21. Shen W, Punyanitya M, Wang ZM, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004; 97:2333–8.
22. Tan BHL, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009; 15:6973–9.
23. Von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010; 1:129–33.
Review
For citations:
Lyadov V.K., Bulanova E.A., Seryakov A.P. Sarcopenia as a leading component of malignant cachexia syndrome. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(1):4-8. (In Russ.)
Views:
83
Email this article 
